HBPT (etidronic acid) acts as
**Core Concept**
HBPT (etidronic acid) is a bisphosphonate drug used in the management of conditions such as osteoporosis, Paget's disease, and tumor-induced hypercalcemia. It acts by inhibiting osteoclast-mediated bone resorption.
**Why the Correct Answer is Right**
HBPT etidronic acid works by binding to hydroxyapatite in bone, which prevents osteoclasts from resorbing bone. This is achieved through the inhibition of farnesyl pyrophosphate synthase (FPPS), an enzyme crucial for the mevalonate pathway, which is necessary for the activation of osteoclasts. The inhibition of FPPS leads to the accumulation of mevalonate and its downstream products, ultimately resulting in the apoptosis of osteoclasts.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect - This option is not relevant to the mechanism of action of HBPT etidronic acid.
**Option B:** Incorrect - This option is related to the mechanism of action of bisphosphonates but is not the primary action of HBPT etidronic acid.
**Option C:** Incorrect - This option is related to the mechanism of action of a different class of drugs.
**Clinical Pearl / High-Yield Fact**
Bisphosphonates like HBPT etidronic acid have a long skeletal half-life, which allows for once-daily dosing and minimizes the risk of renal toxicity associated with other bisphosphonates.
**Correct Answer: B. Inhibits osteoclast-mediated bone resorption.**